



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/674,087	09/29/2003	Jianzhu Chen	0492611-0507 (MIT 10396)	2178
24280 7590 02/22/2010 CHOATE, HALL & STEWART LLP TWO INTERNATIONAL PLACE BOSTON, MA 02110			EXAMINER CHONG, KIMBERLY	
			ART UNIT 1635	PAPER NUMBER
			NOTIFICATION DATE 02/22/2010	DELIVERY MODE ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

patentdocket@choate.com

Office Action Summary	Application No. 10/674,087	Applicant(s) CHEN ET AL.	
	Examiner KIMBERLY CHONG	Art Unit 1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 November 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 101-110 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 101-110 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Status of Application/Amendment/Claims

Applicant's response filed 11/09/2009 has been considered. Rejections and/or objections not reiterated from the previous office action mailed 08/07/2009 are hereby withdrawn. The following rejections and/or objections are either newly applied or are reiterated and are the only rejections and/or objections presently applied to the instant application. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 101-110 are currently under examination. No claims are allowable.

Applicants have amended dependent claims 101 and 102 because they state that although on PTO 326 indicates that claims 101 and 102 have been rejected, the Examiner did not include claims 101 and 102 in any of the actual rejections. Thus Applicant states they "concluded" that claims 101 and 102 were not rejected and included on the PTO 326 in error. Applicant further submits that claims 101 and 102 are allowable if rewritten in independent form and therefore "*solely* for the purpose of furthering prosecution" Applicant has submitted these claims in independent form as well as new claims.

Despite the fact that claims 101 and 102 were noted on the PTO 326 form as rejected and *not allowable*, claims 101 and 102 were stated as currently under examination under the heading of Status of Application/Amendment/Claims recited on page 2 of the Office action *and* most importantly the subject matter of independent

Art Unit: 1635

claims 101 and 102 were clearly rejected in the 103 claim rejection beginning on page 4 with Astriab-Fisher et al. it is difficult to conceive that Applicant would come to the conclusion that these claims were allowable and even more difficult to understand how this expedites prosecution. In the future, Applicant is encouraged to call the Examiner for clarification rather than assuming Examiner made an error in not indicating allowable claims and this would in fact expedite prosecution. The rejection below is reiterated against claims 101 and 102 and also includes new claims 103-110 and for clarity none of these claims have been found allowable.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 101-110 are rejected under 35 U.S.C. 103(a) as being unpatentable over Abe et al. (European Journal of Pharm. Sci, 2001 of record IDS filed 09/12/2005), Tuschl et al. (WO 02/44321 of record), Astriab-Fisher et al. teach (Biochemical Pharmacology, 2000. Vol. 60, pp.83-90 of record), Lewis et al. (US 2003/0125281 of record) and evidenced by Caplen (Expert Opin. Biol. Ther. 2003, 3(4): 575-586 of record) and Trubetskoy et al. (US 2004/0162235 of record).

The claims are drawn to methods of inhibiting a transcript associated with a influenza virus, or methods of treating an influenza virus nucleoprotein or a clinical

Art Unit: 1635

condition associated with overexpression or inappropriate expression of an influenza transcript, comprising administering an siRNA in combination with a cationic peptide, and wherein said administration is vascular.

Abe et al. teach targeting an antisense compound to a gene encoding the influenza viral nucleoprotein (NP). Abe et al. teach sequence specific inhibition of expression in vitro using said antisense compounds delivered using liposomes (see Table 2). Abe et al. teach intravenous delivery of antisense compounds to mouse infected with influenza virus and teach a reduction in the viral target mRNA and a decrease in virus titer in the lungs (see pages 65-68). Abe et al. do not teach using a siRNA targeted to a viral nucleoprotein or teach using a siRNA and a cationic peptide, do not teach administration by inhalation or as an aerosol and further do not teach using an antibody or ligand to specifically target a cell.

Tuschl et al. teach the use of siRNA compounds to inhibit gene expression. Tuschl et al. teach siRNA are the new alternative to antisense compounds and have improved efficacy and safety (see page 3). Tuschl et al. teach a method of using siRNA to infect cells of mammals and teach modulating of the function of a target gene in numerous tissues and cells, such as a viral target gene (see page 8). Tuschl et al. teach the siRNA can be delivered using a carrier system (see page 8) and teach the siRNA can be administered by injection. Additionally, Tuschl et al. teach a vector capable of expression of a siRNA (see page 7).

Astriab-Fisher et al. teach inhibition of gene expression using oligonucleotides conjugated to cationic peptides. Astriab-Fisher et al. teach one of the major problems

Art Unit: 1635

with the use of oligonucleotides is delivery to the cytoplasm and nucleus of the cells and teach it was known in the art to try and overcome this problem by complexing the oligonucleotide with liposomes but one major liability with this approach is that liposomes do not work well in the presence of serum and therefore are not effective in vivo situations (see page 83). Astraib-Fisher et al. teach the use of delivery cationic peptides such as Tat protein and Antennapeida protein which are capable of intracellular delivery of molecules across cell membranes (see page 83-85).

Lewis et al. teach siRNA molecules and teach compositions comprising siRNA and delivery agents such as polycation agents, polylysine or peptides that can be used to delivery siRNA into cells to inhibit the expression of a desired gene (see paragraphs 0029-0079). Lewis et al. further teach the use of cell-targeting signals that can be complexed with the siRNA to enhance the cellular binding to receptors on cells (see paragraph 0082).

It would have been obvious to one of skill in the art to substitute a siRNA molecule for the antisense molecule in the method of inhibiting an influenza viral gene taught by Abe et al. It would have further been obvious to use the cationic peptide to efficiently deliver the siRNA to the cell of interest and further obvious to incorporate an antibody to the peptide-siRNA complex for targeted delivery to a specific cell type.

It was well known at the time of the instant invention that silencing of gene expression using siRNA was more efficient and sequence specific as compared to antisense or ribozyme technologies. One of ordinary skill in the art would have clearly substituted the antisense compound taught by Abe et al. with a siRNA in a method of

Art Unit: 1635

inhibiting an influenza viral gene expression in infected organs of a subject. Therefore, because as demonstrated by Tuschl et al., siRNAs were known to be more efficient at silencing gene expression, one of ordinary skill in the art at the time the invention was made would have clearly substituted the antisense molecule for a siRNA to target the influenza viral NP gene.

It was further well known that one of the major problems with the use of oligonucleotides is delivery to the cytoplasm and nucleus of the cells and that siRNA has the same delivery issues as antisense oligonucleotides as evidenced by Caplen (Expert Opin. Biol. Ther. 2003, 3(4): 575-586) who states “[m]any of the problems associated with developing RNAi as an effective therapeutic are the same as encountered with previous therapy approaches. The key issues of delivering nucleic acids to the required tissue and cell type, while ensuring an appropriate level of efficacy with minimum toxicity induced by the vector system, have been problems the gene therapy field has struggled with for over a decade now” (see page 581, last paragraph). It was also well known in the art that using peptide-nucleic acid complexes could overcome these problems and therefore one of ordinary skill in the would have use a delivery agent as taught by Astriab-Fisher et al. and Lewis et al. to complex with siRNA in the method of inhibiting the influenza NP viral gene.

There would have been a reasonable expectation of success at using a cationic peptide for delivery of a siRNA into cells, given Astriab-Fisher et al. teach delivery of a nucleic acid using a cationic peptide and as evidenced by Trubetskoy et al., who teach

Art Unit: 1635

routine methods of using compositions comprising siRNA and cationic agents to delivery said siRNA into cells in vivo (see Example 7).

Thus in the absence of evidence to the contrary, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 101-110 are provisionally rejected under the judicially created doctrine of double patenting over claims 12, 22 and 24-27 of copending Application No.

11/259,434. This is a provisional double patenting rejection since the conflicting claims

Art Unit: 1635

have not yet been patented. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims and the claims of the patent are drawn to patently indistinguishable subject matter.

The claims are drawn to methods of inhibiting a transcript associated with a influenza virus, or methods of treating or preventing or treating an influenza virus or a clinical condition associated with overexpression or inappropriate expression of an influenza transcript, comprising administering an siRNA in combination with a cationic polymer, wherein said administration may be intravenous or intranasal, or is inhaled, or is delivered by aerosol, or wherein said inhibition is in the lung, or not in the lung, or wherein said combination is delivered with a delivery enhancing agent which may be an antibody or fragment or ligand.

Claims 12, 22 and 24-27 of co-pending Application No. 11/259,434 are drawn to a method of treating influenza virus infection comprising contacting the host cells with an antiviral compound comprising an antisense oligonucleotide wherein the oligonucleotide is conjugated to a polypeptide that enhances uptake of the compound into the host cell. Co-pending Application No. 11/259,434 does not teach inhibiting expression of influenza virus or treating influenza virus using a siRNA and do not teach using a delivery agent such as a cationic polymer. Tuschl et al. (WO 02/44321) teach the use of siRNA compounds to inhibit gene expression. Tuschl et al. teach siRNA are the new alternative to antisense compounds and have improved efficacy and safety (see page 3). Gautam et al. (Molecular Therapy 2000, Vol. 2(1); 63-70) teach a method of efficiently delivery nucleic acids along with a cationic polymer, polyethyleneimine, into

Art Unit: 1635

the lungs of a mouse (see Figure 1). It would have been obvious and one of skill in the art would have been motivated to use an siRNA in a method of treating influenza virus given Tuschl et al. teach siRNAs are the new alternative to antisense therapeutics.

Thus claims 12, 22 and 24-27 of co-pending Application No. 11/259,434 anticipates claims 101-110 of the instant application. This is a provisional obviousness-type double patenting rejection.

No claims are allowable.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kimberly Chong whose telephone number is 571-272-3111. The examiner can normally be reached Monday thru Friday between 7-4 pm.

If attempts to reach the examiner by telephone are unsuccessful please contact Tracy Vivlemore at 571-272-2914. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service

Art Unit: 1635

center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For more information about the PAIR system, see <http://pair-direct.uspto.gov>.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

/Kimberly Chong/
Primary Examiner
Art Unit 1635